XIIlab to Issue 10 Billion Won in Convertible Bonds
Bitget2026/11/06 05:21- XIIlab plans a KRW 10 billion private placement of unsecured convertible bonds to fund AI data center operations.
- Payment is scheduled for November 16, 2026; the zero-interest bonds mature November 16, 2031.
- Conversion at KRW 8,106 per share could create 1,233,654 common shares, equivalent to 13.14% of existing shares.
- Bondholders can seek early redemption from May 16, 2029; the issuer or designated buyers can call up to 50%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
Forge Nano completes acquisition of HzO
Crypto prices
More
